Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 85.05% is 2181% above its 5-year average of 3.73%, near the high end of its 5-year range (3.19%–98.12%).
As of the fiscal period ended Tuesday, June 30, 2026. 20.96% above its 12-month average of 70.31%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 85.05%.
DEBT TO ASSETS RATIO
85.05%
DEBT TO ASSETS RATIO AVG TTM
70.31%
DEBT TO ASSETS RATIO AVG 3Y
35.22%
DEBT TO ASSETS RATIO AVG 5Y
3.73%
DEBT TO ASSETS RATIO AVG 10Y
3.75%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+20.96%
CURRENT VS 3Y AVG
+141.47%
CURRENT VS 5Y AVG
+2181.00%
CURRENT VS 10Y AVG
+2168.90%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 810 covered companies
CURRENT VS SECTOR MEDIAN
+94397.58%
vs the sector median at left
AnaptysBio, Inc.
Market Cap
$1.41B
Debt to Assets Ratio
85.05%
TTM Avg
70.31%
3Y Avg
35.22%
5Y Avg
3.73%
Market Cap
$1.41B
Debt to Assets Ratio
0.48%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
Debt to Assets Ratio
0.95%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.43B
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.46B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AnaptysBio, Inc. (ANAB) | $1.41B | 85.05% | 70.31% | 35.22% | 3.73% |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 0.48% | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | 0.01% | N/A | N/A | N/A |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | 0.95% | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | 0.03% | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.43B | 0.11% | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.45B | 0.21% | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 0.02% | N/A | N/A | N/A |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.46B | 0.02% | N/A | N/A | N/A |
Debt/Assets
85.0%
Debt/Equity
25.47
Current Ratio
5.61
Interest Coverage
0.6x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 85.05% |
| 2026-03-31 | 84.13% |
| 2025-12-31 | 79.76% |
| 2025-09-30 | 98.12% |
| 2025-06-30 | 4.50% |
| 2025-03-31 | 3.69% |
| 2024-12-31 | 3.31% |
| 2024-09-30 | 3.34% |
| 2024-06-30 | 3.97% |
| 2024-03-31 | 80.72% |
| 2023-12-31 | 3.94% |
| 2023-09-30 | 3.74% |
| 2023-06-30 | 3.61% |
| 2023-03-31 | 3.45% |
| 2022-12-31 | 3.19% |
| 2022-09-30 | 3.21% |
| 2022-06-30 | 3.35% |
| 2022-03-31 | 3.29% |
| 2021-12-31 | 3.26% |
| 2021-09-30 | 4.93% |
| 2021-06-30 | 4.87% |
| 2021-03-31 | 0.05% |
| 2020-12-31 | 0.08% |
| 2020-09-30 | 0.23% |
| 2020-06-30 | 0.23% |
| 2020-03-31 | 0.21% |
| 2019-12-31 | 0.67% |
| 2019-09-30 | 0.87% |
| 2019-06-30 | 1.17% |
| 2019-03-31 | 1.47% |
| 2018-12-31 | 1.62% |
| 2018-09-30 | 1.90% |
| 2018-06-30 | 3.81% |
| 2018-03-31 | 4.24% |
| 2017-12-31 | 4.39% |
| 2017-09-30 | 11.71% |
| 2017-06-30 | 10.82% |
| 2017-03-31 | 10.65% |
| 2016-12-31 | 22.21% |
| 2016-09-30 | 8.93% |
| 2016-06-30 | 8.49% |
| 2016-03-31 | 9.03% |
| 2015-12-31 | 8.75% |
| 2015-09-30 | 8.22% |
| 2015-06-30 | 22.35% |
| 2015-03-31 | 21.14% |
| 2014-12-31 | 19.64% |
